CIPLA : PARTNERS WITH QILU PHARMA FOR KEYTRUDA® BIOSIMILAR IN US

• Strategic partnership for exclusive licensing and supply of QL2107, a biosimilar to Keytruda® (pembrolizumab), for the United States. • Qilu responsible for development, regulatory registration and supply; Cipla USA Inc. for commercialization. • Collaboration aims to address growing burden of cancer and improve access to advanced biologic therapies. • Partnership reflects Cipla's confidence in biosimilars and supports its oncology strategy. • Aligns with strategy to expand the biosimilar portfolio.

Cipla Limited

Open attachment

← Back to feed